Amgen
AMGN • NASDAQ
Amgen is a drug manufacturers - general company in the healthcare sector trading on NASDAQ, led by CEO Robert A. Bradway, with a market cap of $202.02B.
CEORobert A. Bradway
Market Cap$202.02B
Drug Manufacturers - General
Healthcare
Employees26.7K
Websiteamgen.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Amgen
Date
Thursday, April 30, 2026 (in 2 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$4.81
Revenue Estimate
$8.6B
Earnings History
Past 12 earnings reports for Amgen
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 3, 2026 | Q4 2025 | $5.29Est: $4.75 | +11.4% | $9.9BEst: $9.5B | +4.2% |  10-K |
| Nov 4, 2025 | Q3 2025 | $5.64Est: $5.01 | +12.6% | $9.6BEst: $9.0B | +6.7% | 10-Q |
| Aug 5, 2025 | Q2 2025 | $6.02Est: $5.27 | +14.2% | $9.2BEst: $8.9B | +3.2% | 10-Q |
| May 1, 2025 | Q1 2025 | $4.90Est: $4.30 | +14.0% | $8.1BEst: $8.1B | +1.1% | 10-Q |
| Feb 4, 2025 | Q4 2024 | $5.31Est: $5.08 | +4.5% | $9.1BEst: $8.9B | +2.3% | 10-K |
| Oct 30, 2024 | Q3 2024 | $5.58Est: $5.11 | +9.2% | $8.5BEst: $8.5B | -0.2% | 10-Q |
| Aug 6, 2024 | Q2 2024 | $4.97Est: $5.00 | -0.6% | $8.4BEst: $8.3B | +0.7% | 10-Q |
| May 2, 2024 | Q1 2024 | $3.96Est: $3.87 | +2.3% | $7.4BEst: $6.9B | +7.3% | 10-Q |
| Feb 6, 2024 | Q4 2023 | $4.71Est: $4.62 | +1.9% | $8.2BEst: $8.1B | +0.8% | 10-K |
| Oct 31, 2023 | Q3 2023 | $4.96Est: $4.66 | +6.4% | $6.9BEst: $6.9B | -0.6% | — |
| Aug 3, 2023 | Q2 2023 | $5.00Est: $4.49 | +11.4% | $7.0BEst: $6.7B | +4.6% | 10-Q |
| Apr 27, 2023 | Q1 2023 | $3.98Est: $3.85 | +3.4% | $6.1BEst: $6.2B | -1.1% | — |